Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
QuintilesIMS
McKesson
Chinese Patent Office
Citi
Baxter
Cipla
Daiichi Sankyo
Moodys
AstraZeneca

Generated: August 17, 2017

DrugPatentWatch Database Preview

Lesinurad - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for lesinurad and what is the scope of lesinurad freedom to operate?

Lesinurad
is the generic ingredient in one branded drug marketed by Ironwood Pharms Inc and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lesinurad has one hundred and fifty-seven patent family members in thirty-eight countries.

One supplier is listed for this compound.

Summary for Generic Name: lesinurad

Tradenames:1
Patents:7
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list24
Clinical Trials: see list17
Patent Applications: see list61
Drug Prices:see low prices
DailyMed Link:lesinurad at DailyMed

Pharmacology for Ingredient: lesinurad

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: lesinurad

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,481,581S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase► Subscribe
7,435,752N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors► Subscribe
8,552,043N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors► Subscribe
8,242,154Compounds, compositions and methods of using same for modulating uric acid levels► Subscribe
7,947,721S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: lesinurad

Country Document Number Estimated Expiration
European Patent Office2328879► Subscribe
Ukraine109172► Subscribe
Mexico2011002450► Subscribe
Japan2012184234► Subscribe
Japan2012502049► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LESINURAD

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0160027 00203Estonia► SubscribePRODUCT NAME: LESINURAAD;REG NO/DATE: EU/1/15/1080 22.02.2016
C0031France► SubscribePRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222
0825Netherlands► SubscribePRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222
169Luxembourg► SubscribePRODUCT NAME: LESINURAD , OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION DATE: 20160222
2016 00034Denmark► SubscribePRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Baxter
Farmers Insurance
McKesson
QuintilesIMS
Deloitte
Fish and Richardson
Julphar
Colorcon
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot